. Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunological reviews. 2014; 257(1): 14-38.
. Noori-Daloii MR, Tabarestani S. Molecular Genetics and gene therapy in breast cancer. The Journal of Faculty of Medicine, Sabzevar University of Medical Science. 2010; 17: 74-87. [in Persian]
. Noori-Daloii MR, Zekri A. Aurora kinase family roles in cancer diagnosis and treatment. Medical Science Journal of Islamic Azad University. 2011; 21: 17-81. [in Persian]
. Noori-Daloii MR. Medical molecular genetics in the third millennium. Tehran, Iran: Samer Publication; 2012. (in Persian)
. Noori-Daloii MR, ed. Emery’s elements of medical genetics. 8th ed. Tehran, Iran: Jame-e-negar and Salemi Publication; 2017. (in Persian)
. Immunotherapy. Experimental biology and medicine. 2015; 240(8): 1087-1098.
. Noori-Daloii MR, Ebrahimzadeh-Vesal R. Telomerase and its inhibition in cancer, prevention and gene therapy in prostate cancer.Razzi J 1999; 11: 11-112. [in Persian]
. Suryadevara, Carter M, et al. Are BiTEs the “missing link” in cancer therapy? Oncoimmunology. 2015;4(6): e1008339.
.Miao, Hongsheng, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One. 2014; 9(4): e94281.
. Firor A.E, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Experimental biology and medicine. 2015; 240(8) 1087-1098.
. Pircher M, Schirrmann T, Petrausch U. T cell engineering. Immuno-Oncology. Vol. 42. Karger Publishers. 2015; 110-135.
. Dai H, et al. Chimeric antigen receptors modified T-cells for cancer therapy. Journal of the National Cancer Institute. 2016; 108(7): djv439.
. Beatty G.L, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer immunology research. 2014; 2(2): 112-120.
. Smith A.J, et al. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy. 2016; 2(2): 59-68.
. Gargett T, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Molecular Therapy. 2016; 24(6): 1135-1149.
. Van Der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nature reviews. Drug discovery. 2015; 14(7): 499.
. Noori-Daloii MR, Fazilaty H, Tabrizi M. Cancer metastasis, genetic and microenvironmental factors of distant tissue: A review article. Tehran University of Medical Science. 2013; 70(11).
. Grada Z, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy-Nucleic Acids. 2013; 2.
. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nature Reviews Clinical Oncology; 2017: nrclinonc-2017.
. Chmielewski M, Hombach A.A, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma." Immunological reviews. 2014; 257(1): 83-90.
. Philip B, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014; 124(8): 1277-1287.
. Ren J, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clinical Cancer Research. 2017; 23(9): 2255-2266.
. Whilding L.M, et al. Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. Molecular Therapy. 2017; 25(1): 259-273.
. Rupp L.J, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports. 2017; 7(1): 737.
. Eyquem J, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017; 543(7643): 113-117.
. Jacoby E, et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood. 2016; 127(10): 1361-1370.
. Feinberg B.A, et al. CAR-T cells: the next era in immuno-oncology. The American journal of managed care. 2017; 23(2) Spec No: SP48.
. Harris D.T, Kranz D.M. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends in pharmacological sciences. 2016; 37(3): 220-230.
. Huang, A.C, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545(7652): 60-65.